V1RC10 Inhibitors
V1RC10 inhibitors pertain to a class of chemical compounds that are designed to selectively interact with a specific biological target, commonly a protein or enzyme, which is denoted by the abbreviation "V1RC10". While the specific nature of V1RC10 is not detailed, the inhibitors would typically be molecules that can bind to this target with high specificity, thereby modulating its function. In general, inhibitors can act through various mechanisms, such as competitive, non-competitive, or uncompetitive inhibition, each of which relates to the inhibitor's interaction with the target and its active site or allosteric sites. The design of these inhibitors is grounded in the principles of molecular biology and chemistry, where understanding the structure, conformation, and dynamics of the target molecule is crucial. Advanced techniques such as X-ray crystallography, NMR spectroscopy, and computational modeling are often employed to discern the interaction mechanisms at the atomic level.
The development of V1RC10 inhibitors would involve a meticulous process of chemical synthesis, where organic chemistry plays a central role in constructing compounds with the desired properties. The structure-activity relationship (SAR) is a fundamental concept in the development of such inhibitors, as it guides chemists in modifying parts of the molecule to improve its efficacy in interaction with the target. High-throughput screening methods may be utilized to test a large library of compounds for their ability to bind to the V1RC10 target, followed by iterative cycles of optimization. The physicochemical properties such as solubility, stability, and reactivity are also critical factors that are meticulously tuned during the synthesis process. The aim is to produce a chemical entity that exhibits high specificity and potency towards the V1RC10 target while minimizing interaction with other molecules, thus ensuring a high degree of selectivity in its action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin disrupts the PI3K/AKT signaling pathway, which in turn can lead to reduced phosphorylation and activation of V1RC10, as this protein may be downstream of PI3K signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another specific inhibitor of PI3K. Similar to wortmannin, LY294002's inhibition of PI3K can prevent the activation of the AKT pathway and thus decrease the phosphorylation state and activity of V1RC10 if it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically binds to and inhibits mTOR (mechanistic target of rapamycin), which is part of two complexes, mTORC1 and mTORC2. The inhibition of these complexes can downregulate the pathways that may lead to V1RC10 activation, particularly if V1RC10 is involved in cell growth or survival processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK1/2, which are upstream of ERK1/2 in the MAPK/ERK pathway. By inhibiting MEK, PD98059 can attenuate the activation of ERK, potentially leading to reduced activation of V1RC10 if it's regulated by the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a selective inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway. This can lead to a decrease in the activity of V1RC10, assuming V1RC10's activity is modulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 MAPK, SB203580 can reduce the activation of transcription factors and other proteins that are regulated by this kinase, potentially decreasing the activity of V1RC10 if it's involved in the p38 MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which modulates various cellular activities including cell proliferation and apoptosis. Inhibiting JNK can lead to reduced activity of V1RC10 if V1RC10 is part of JNK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Src kinases are involved in multiple signaling pathways, and inhibition by PP2 can lead to decreased activity of V1RC10 if Src signaling regulates this protein. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins marked for destruction. While it mainly targets proteins for degradation, it can also indirectly decrease the activity of V1RC10 by affecting its turnover or the turnover of regulatory proteins. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting EGFR, Gefitinib can interrupt downstream signaling pathways that might regulate the activity of V1RC10. | ||||||